{"createdAt":"8/2/2020, 2:38:13 PM","timestamp":1596393493544,"Company ID number":"656","DMX_ISSUER_NAME":"ZHEJIANG NHU COMPANY LTD.","DMX_ISSUER_ID":"IID000000002131925","Country of Classification":"CHINA","name":"Zhejiang Nhu Co Ltd ","code":"002001","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"浙江新和成股份有限公司_胡柏藩","group":"board","name":"胡柏藩","title":"董事长,董事","isMale":true,"age":"58","degree":"硕士","salary":"210.0万","stockAmount":"966.8万","description":"胡柏藩，男，1962年生，浙江大学工商管理专业研究生结业，高级经济师，中共党员。2008年11月起至今任新和成控股集团有限公司董事长、总裁。1988年11月创建新昌县有机化工厂并任厂长；1999年2月起任浙江新和成股份有限公司董事长；现兼任浙江新和成股份有限公司董事长、绍兴越秀教育发展有限公司董事长、北京万生药业有限责任公司董事、福元药业有限公司董事、浙江爱生药业有限公司董事、北京和成地产控股有限公司董事等职。曾获中国首届石油和化学工业十大风云人物、浙江省优秀企业家、浙江省优秀教育企业家、浙江省劳动模范，绍兴市首届教育功臣等称号。先后当选为绍兴市第四届、第五届、第六届人大代表，现任浙江省十三届政协委员。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_胡柏剡","group":"board","name":"胡柏剡","title":"副董事长,董事","isMale":true,"age":"53","degree":"硕士","salary":"170.0万","stockAmount":"1014万","description":"胡柏剡，男，1967年生，浙江大学精细化工专业本科，浙江大学工商管理EMBA，高级工程师，中共党员。2008年11月起至今任新和成控股集团有限公司董事，现兼任浙江新和成股份有限公司副董事长、总裁，浙江新和成进出口有限公司董事长，上虞新和成生物化工有限公司、山东新和成药业有限公司、浙江新和成药业有限公司、浙江新和成特种材料有限公司执行董事和绍兴越秀教育发展有限公司董事等职。曾获得全国饲料添加剂科技创新先进工作者、中国化学工业思想政治工作和企业文化建设优秀工作者、浙江省化工学会优秀学会工作者。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_石观群","group":"board","name":"石观群","title":"董事","isMale":true,"age":"49","degree":"大专","salary":"112.0万","stockAmount":"727.6万","description":"石观群，男，1971年生，湖南大学会计系，专科，会计师，中共党员。2008年11月起至今任新和成控股集团有限公司董事。现兼任浙江新和成股份有限公司董事、副总裁、董事会秘书、财务总监，浙江新和成进出口有限公司、新和成（中国香港）贸易有限公司、浙江新赛科药业有限公司、北京万生药业有限责任公司、绍兴越秀教育发展有限公司、浙江爱生药业有限公司、浙江德力装备有限公司、新昌县和成置业有限公司、北京和成地产控股有限公司董事，山东新和成药业有限公司监事等职。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_王学闻","group":"board","name":"王学闻","title":"董事","isMale":true,"age":"51","degree":"大专","salary":"164.0万","stockAmount":"616.5万","description":"王学闻,男,1969年生,中国纺织大学企业管理专科,大专学历。2008年11月起至今任新和成控股集团有限公司董事。2005年4月起任浙江新和成股份有限公司董事、副总裁;兼任浙江新和成进出口有限公司董事、新昌新和成维生素有限公司总经理。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_崔欣荣","group":"board","name":"崔欣荣","title":"董事","isMale":true,"age":"56","degree":"硕士","salary":"0.00","stockAmount":"208.4万","description":"崔欣荣，男，1964年生，本科学历，工程硕士，高级经济师。2008年11月至2014年11月任新和成控股集团有限公司监事，2011年11月至今任新和成控股集团有限公司监事会主席。现兼任浙江新和成股份有限公司董事、福元药业有限公司董事长、浙江德力装备有限公司董事长、浙江爱生药业有限公司董事、绍兴越秀教育发展有限公司董事等职。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_王正江","group":"board","name":"王正江","title":"董事","isMale":true,"age":"51","degree":"硕士","salary":"112.0万","stockAmount":"31.88万","description":"王正江,男,1969年生,中国国籍,无境外永久居留权,硕士,高级工程师,中共党员。2008年4月起担任浙江新和成股份有限公司董事,2004年至2013年4月任上虞新和成生物化工有限公司总经理,2013年6月起任山东新和成氨基酸有限公司总经理。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_周贵阳","group":"board","name":"周贵阳","title":"董事","isMale":true,"age":"45","degree":"大专","salary":"122.0万","stockAmount":"11.48万","description":"周贵阳,男,1975年生,中国国籍,无境外永久居留权,大专,中共党员。2008年至2013年4月担任上虞新和成生物化工有限公司副总经理,2012年1月至今任浙江新和成特种材料有限公司总经理。现兼任浙江春晖环保能源股份有限公司董事、上虞新和成生物化工有限公司监事、浙江新和成药业有限公司监事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_黄灿","group":"board","name":"黄灿","title":"独立董事","isMale":true,"age":"41","degree":"博士","salary":"10.00万","stockAmount":"-","description":"黄灿,男,1979年出生,中国国籍,无境外永久居留权,中共党员,博士,教授、博士生导师。2013年9月至今,任浙江大学管理学院教授、博士生导师,创新创业与战略学系主任,浙江大学创新管理与持续竞争力研究中心常务副主任,知识产权管理研究所联席所长。2016年5月至今任浙江运达风电股份有限公司独立董事,兼任浙江新和成股份有限公司和甘肃上峰水泥股份有限公司独立董事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_韩灵丽","group":"board","name":"韩灵丽","title":"独立董事","isMale":false,"age":"57","degree":"本科","salary":"10.00万","stockAmount":"-","description":"韩灵丽,女,1963年1月出生,中国国籍,无境外永久居留权,本科学历,教授。1984年7月至1988年1月任中南财经大学政法系担任经济法学专业讲师;1988年2月至1998年12月任浙江财经大学财政税务系副教授、教授;1999年1月至2010年12月任浙江财经大学法学院担任教授、副院长、院长;2011年1月至2015年12月任浙江财经大学经济与社会发展研究院教授、院长;2016年1月至今任浙江财经大学土地与城乡发展研究院教授。2015年10月至今担任中源家居独立董事。目前,韩灵丽还兼任浙江浙能电力股份有限公司、德华兔宝宝装饰新材料股份有限公司、浙江新和成股份有限公司、万马科技股份有限公司独立董事,并且曾担任华数传媒股份有限公司的独立董事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_金赞芳","group":"board","name":"金赞芳","title":"独立董事","isMale":false,"age":"44","degree":"博士","salary":"10.00万","stockAmount":"-","description":"金赞芳,女,1976年生,中国国籍,无境外永久居留权,浙江大学环境工程博士,现任浙江工业大学教授。任杭州国泰环保科技有限公司、浙江景兴纸业股份有限公司独立董事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_朱剑敏","group":"board","name":"朱剑敏","title":"独立董事","isMale":false,"age":"56","degree":"硕士","salary":"10.00万","stockAmount":"-","description":"朱剑敏,女,1964年生,中国国籍,无境外永久居留权,上海财经大学财政学专业硕士研究生毕业,高级会计师。1995年3月至2015年10月就职于天健会计师事务所,曾任部门经理,2015年11月至2018年3月担任浙江科惠医疗器械股份有限公司独立董事,2017年7月至今担任浙江新和成股份有限公司独立董事。2015年加入每日互动,现系公司财务负责人、副总经理。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_叶月恒","group":"supervisoryCommittee","name":"叶月恒","title":"监事会主席","isMale":false,"age":"48","degree":"本科","salary":"91.00万","stockAmount":"19.13万","description":"叶月恒,女,1972年生,中国国籍,无境外永久居留权,本科,工程师,中共党员。2007年4月至2011年4月任公司监事、物流总监,2011年4月至2017年3月任公司运营副总裁助理,2017年3月至今任营养品经营事业部副总经理,2011年4月至2014年4月任公司董事,2014年4月至2016年5月任公司监事,2016年5月至今任浙江新和成股份有限公司监事会主席,兼任浙江春晖环保能源股份有限公司董事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_吕锦梅","group":"supervisoryCommittee","name":"吕锦梅","title":"监事","isMale":false,"age":"42","degree":"本科","salary":"0.00","stockAmount":"-","description":"吕锦梅,女,1978年生,中国国籍,无境外永久居留权,本科。2008年2月至2016年3月任新和成控股集团有限公司财务经理,2016年3月至今任新和成控股集团有限公司资金部部长,2011年4月至今任浙江新和成股份有限公司监事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_陈学操","group":"supervisoryCommittee","name":"陈学操","title":"监事","isMale":true,"age":"44","degree":"大专","salary":"49.00万","stockAmount":"-","description":"陈学操,男,1976年生,中国国籍,无境外永久居留权,大专,1998年7月至2004年9月任公司项目科副科长,2004年10月至2012年2月上虞新和成生物化工有限公司副总经理,2012年3月至2016年2月浙江新和成股份有限公司总裁办主任等,2016年3月至今任新昌基地常务副总经理,2016年5月至今任浙江新和成股份有限公司监事。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_梁晓东","group":"supervisoryCommittee","name":"梁晓东","title":"职工监事","isMale":true,"age":"49","degree":"硕士","salary":"78.00万","stockAmount":"19.13万","description":"梁晓东,男,1971年生,郑州工学院化工机械专业本科,浙江工业大学工商管理研究生结业,工程师,中共党员。2008年11月起至今任新和成控股集团有限公司监事;现兼任浙江新和成股份有限公司监事、副总工程师。","lastUpdated":"2017-06-22"},{"id":"浙江新和成股份有限公司_邱金倬","group":"supervisoryCommittee","name":"邱金倬","title":"职工监事","isMale":true,"age":"44","degree":"本科","salary":"86.00万","stockAmount":"9.581万","description":"邱金倬,男,1976年生,中国国籍,无境外永久居留权,本科。2008年2月至2014年2月任山东新和成药业有限公司常务副总经理,2011年4月至今任浙江新和成股份有限公司监事,2014年2月至今任山东新和成药业有限公司总经理。","lastUpdated":"2017-06-22"},{"id":"浙江新和成股份有限公司_胡柏剡","group":"manager","name":"胡柏剡","title":"总裁","isMale":true,"age":"53","degree":"硕士","salary":"170.0万","stockAmount":"1014万","description":"胡柏剡，男，1967年生，浙江大学精细化工专业本科，浙江大学工商管理EMBA，高级工程师，中共党员。2008年11月起至今任新和成控股集团有限公司董事，现兼任浙江新和成股份有限公司副董事长、总裁，浙江新和成进出口有限公司董事长，上虞新和成生物化工有限公司、山东新和成药业有限公司、浙江新和成药业有限公司、浙江新和成特种材料有限公司执行董事和绍兴越秀教育发展有限公司董事等职。曾获得全国饲料添加剂科技创新先进工作者、中国化学工业思想政治工作和企业文化建设优秀工作者、浙江省化工学会优秀学会工作者。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_石观群","group":"manager","name":"石观群","title":"董事会秘书,副总裁,财务总监","isMale":true,"age":"49","degree":"大专","salary":"112.0万","stockAmount":"727.6万","description":"石观群，男，1971年生，湖南大学会计系，专科，会计师，中共党员。2008年11月起至今任新和成控股集团有限公司董事。现兼任浙江新和成股份有限公司董事、副总裁、董事会秘书、财务总监，浙江新和成进出口有限公司、新和成（中国香港）贸易有限公司、浙江新赛科药业有限公司、北京万生药业有限责任公司、绍兴越秀教育发展有限公司、浙江爱生药业有限公司、浙江德力装备有限公司、新昌县和成置业有限公司、北京和成地产控股有限公司董事，山东新和成药业有限公司监事等职。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_王学闻","group":"manager","name":"王学闻","title":"副总裁","isMale":true,"age":"51","degree":"大专","salary":"164.0万","stockAmount":"616.5万","description":"王学闻,男,1969年生,中国纺织大学企业管理专科,大专学历。2008年11月起至今任新和成控股集团有限公司董事。2005年4月起任浙江新和成股份有限公司董事、副总裁;兼任浙江新和成进出口有限公司董事、新昌新和成维生素有限公司总经理。","lastUpdated":"2017-07-13"},{"id":"浙江新和成股份有限公司_郑根土","group":"manager","name":"郑根土","title":"副总裁","isMale":true,"age":"58","degree":"硕士","salary":"71.00万","stockAmount":"-","description":"郑根土,男,1962年生,中国国籍,无境外永久居留权,本科,工程硕士,中共党员。历任浙江工程设计有限公司(原巨化集团公司设计院)项目经理、工艺室副主任、技术部经理/副总工程师、总工程师、副总经理,高级工程师;浙江衢化氟化学有限公司高级工程师副总经理(分管项目建设、企业管理);浙江巨化集团公司石化材料事业部(分管锦纶公司/硫酸厂)教授级高级工程师总经理兼厂长;浙江开尔新材料股份有限公司董事/总经理。","lastUpdated":"2018-10-08"}],"companyName":"浙江新和成股份有限公司","province":"浙江省","englishName":"Zhejiang Nhu Co Ltd","industry":"医药生物 — 化学制药","website":"www.cnhu.com","mainBusiness":"从事营养品、香精香料、高分子复合新材料和原料药的生产和销售","productsName":["营养品","香精香料"],"actualController":"胡柏藩、胡柏剡","actualControllerSharePercentage":"30.44、2.45%","registeredCapital":"21.49亿元","employeeAmount":"9971","phone":"86-0575-86017157","location":"浙江省绍兴市新昌县七星街道新昌大道西路418号","chineseDescription":"浙江新和成股份有限公司是国家重点高新技术企业之一,公司主要从事药品、保健品、医药原料药、香精香料、食品添加剂、饲料添加剂等系列50多个产品的生产和销售.公司的主要产品为维生素E类、维生素A类和乙氧甲叉,主要用于饲料添加剂、保健品和原料药。","foundedDate":"1999-04-05","goPublicDate":"2004-06-25","companyHistory":"浙江新和成股份有限公司（以下简称公司或本公司）系经原浙江省人民政府证券委员会浙证委[1999]9号文批准，由新昌县合成化工厂（2009年11月17日更名为新和成控股集团有限公司）联合张平一、袁益中、石程、胡柏剡、石观群、王学闻、石三夫、崔欣荣和王旭林等九名自然人共同发起设立，于1999年4月5日在浙江省工商行政管理局注册登记，总部位于浙江省绍兴市。公司现持有统一社会信用代码为91330000712560575G的营业执照，注册资本108,891.90万元，股份总数108,891.90万股（每股面值1元）。\n　　其中，有限售条件的流通股份为27,180,937股；无限售条件的流通股份为2,121,481,363股。公司股票已于2004年6月25日在深圳证券交易所挂牌交易。收起▲","shareholders":[{"organizationId":"","holderName":"新和成控股集团有限公司","totalShare":"10.43亿","sharePercentage":"48.55%"},{"organizationId":"","holderName":"香港中央结算有限公司","totalShare":"4816.06万","sharePercentage":"2.24%"},{"organizationId":"","holderName":"上海重阳战略投资有限公司-重阳战略汇智基金","totalShare":"3857.97万","sharePercentage":"1.80%"},{"organizationId":"","holderName":"华安未来资产-工商银行-杭州丰信投资合伙企业(有限合伙)","totalShare":"2831.00万","sharePercentage":"1.32%"},{"organizationId":"","holderName":"华安未来资产-工商银行-杭州锐智投资合伙企业(有限合伙)","totalShare":"2544.57万","sharePercentage":"1.18%"},{"organizationId":"","holderName":"全国社保基金五零三组合","totalShare":"2000.00万","sharePercentage":"0.93%"},{"organizationId":"","holderName":"招商银行股份有限公司-睿远成长价值混合型证券投资基金","totalShare":"1994.54万","sharePercentage":"0.93%"},{"organizationId":"","holderName":"三花控股集团有限公司","totalShare":"1487.50万","sharePercentage":"0.69%"},{"organizationId":"","holderName":"银河资本-浙商银行-银河资本-鑫鑫一号资产管理计划","totalShare":"1487.50万","sharePercentage":"0.69%"},{"organizationId":"","holderName":"全国社保基金一一四组合","totalShare":"1301.38万","sharePercentage":"0.61%"}],"englishDescription":"ZHEJIANG NHU COMPANY LTD. is a China-based company principally engaged in the manufacture and sales of nutrition products. The Company is also involved in the production and sales of flavors and fragrances, high polymer new materials, as well as bulk pharmaceutical chemicals. The Company's main products include vitamin E, vitamin A, astaxanthin, raspberry ketone and linalool. The Company distributes its products within domestic market and to overseas markets. ","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"24.72","Price to sales (ttm)":"7.53","Price to book (mrq)":"3.56","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"47.51","Lt debt to equity (mrq)":"24.44","Return on investment (ttm)":"12.45","Return on equity (ttm)":"9.77","Income statement":{"Revenue":"7,620.98","Total revenue":"7,620.98","Cost of revenue, total":"4,035.81","Gross profit":"3,585.18","Selling/general/admin. expenses, total":"660.84","Research & development":"396.14","Depreciation/amortization":"100.59","Interest exp.(inc.),net-operating, total":"(32.38)","Unusual expense (income)":"(31.24)","Other operating expenses, total":"(75.42)","Total operating expense":"5,054.34","Operating income":"2,566.65","Other, net":"2.05","Net income before taxes":"2,568.69","Provision for income taxes":"392.14","Net income after taxes":"2,176.55","Minority interest":"(7.94)","Net income before extra. items":"2,168.62","Net income":"2,168.62","Income available to com excl extraord":"2,168.62","Income available to com incl extraord":"2,168.62","Diluted net income":"2,168.62","Diluted weighted average shares":"2,148.66","Diluted eps excluding extraord items":"1.01","Dps - common stock primary issue":"0.50","Diluted normalized eps":"1.00","Gain (loss) on sale of assets":"(0.48)"},"Balance sheet":{"Cash":"0.01","Cash & equivalents":"3,299.64","Short term investments":"1,400.00","Cash and short term investments":"4,699.65","Accounts receivable - trade, net":"1,561.39","Total receivables, net":"3,199.07","Total inventory":"2,032.60","Prepaid expenses":"66.47","Other current assets, total":"2,572.83","Total current assets":"12,570.62","Property/plant/equipment, total - gross":"17,096.37","Accumulated depreciation, total":"(3,223.13)","Property/plant/equipment, total - net":"13,873.24","Intangibles, net":"1,314.41","Long term investments":"306.14","Other long term assets, total":"437.11","Total assets":"28,501.52","Accounts payable":"1,649.40","Accrued expenses":"294.69","Notes payable/short term debt":"3,940.92","Current port. of  lt debt/capital leases":"654.45","Other current liabilities, total":"234.74","Total current liabilities":"6,774.21","Long term debt":"3,897.54","Total long term debt":"3,897.54","Total debt":"8,492.91","Deferred income tax":"79.27","Minority interest":"52.48","Other liabilities, total":"849.90","Total liabilities":"11,653.40","Common stock, total":"2,148.66","Additional paid-in capital":"4,527.82","Retained earnings (accumulated deficit)":"10,133.87","Other equity, total":"37.77","Total equity":"16,848.12","Total liabilities & shareholders' equity":"28,501.52","Total common shares outstanding":"2,148.66","Tangible book value per share, common eq":"7.23","Goodwill, net":"2.24"},"Cash flow":{"Cash receipts":"7,336.92","Cash payments":"(3,622.98)","Cash taxes paid":"(292.24)","Changes in working capital":"(1,319.38)","Cash from operating activities":"2,102.32","Capital expenditures":"(4,575.79)","Other investing cash flow items, total":"213.16","Cash from investing activities":"(4,362.63)","Financing cash flow items":"(82.12)","Total cash dividends paid":"(1,713.25)","Issuance (retirement) of debt, net":"4,853.43","Cash from financing activities":"3,058.06","Foreign exchange effects":"16.12","Net change in cash":"813.87"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"29.44","52 Week High":"32.40","52 Week Low":"19.20","Pricing date":"","10 Day Average Trading Volume":"38.39","Market Capitalization":"63,256.62","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"673.95","Beta":"0.58","1 Day Price Change":"-0.20","13 Week Price Return (Daily)":"7.88","26 Week Price Return (Daily)":"24.90","5 Day Price Return (Daily)":"3.12","52 Week Price Return (Daily)":"40.53","Year To Date Price Return (Daily)":"26.57","Month to Date Price Return (Daily)":"1.17","Price Relative to S&P500 (4 Week)":"-5.26","Price Relative to S&P500 (13 Week)":"-15.19","Price Relative to S&P500 (26 Week)":"-2.17","Price Relative to S&P500 (52 Week)":"-4.50","Price Relative to S&P500 (YTD)":"-3.20"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.01","EPS excl. Extra Items (TTM)":"1.19","EPS Normalized (Annual)":"1.00","Revenue per Share (Annual)":"3.55","Revenue per Share (TTM)":"3.91","Book Value (Per Share Annual)":"7.84","Book Value (Per Share Quarterly)":"8.27","Tangible Book Value (Per Share Annual)":"7.23","Tangible Book Value (Per Share Quarterly)":"7.66","Cash Per Share (Per Share Annual)":"2.19","Cash Per Share (Per Share Quarterly)":"2.38","Cash Flow (Per Share Annual)":"1.27","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.50","Dividends (Per Share TTM)":"0.50","EBITD (Per Share TTM)":"1.39","EPS Basic excl. Extra Items (Annual)":"1.01","EPS Basic excl. Extra Items (TTM)":"1.19","EPS incl. Extra Items (Annual)":"1.01","EPS incl. Extra Items (TTM)":"1.19","Free Cash Flow (Per Share TTM)":"-1.79","Dividend (Per Share 5Y)":"0.42"},"Valuation":{"P/E excl. Extra Items (Annual)":"29.17","P/E excl. Extra Items (TTM)":"24.72","P/E Normalized (Annual)":"29.53","Price to sales (Annual)":"8.30","Price to sales (TTM)":"7.53","Price to Tangible Book (Annual)":"4.07","Price to Tangible Book (Quarterly)":"3.84","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"3.75","Price to Book (Quarterly)":"3.56","P/E Basic excl. Extra Items (TTM)":"22.92","P/E excl. Extra Items High (TTM)":"48.36","P/E excl. Extra Items Low (TTM)":"9.64","P/E incl. Extra Items (TTM)":"24.72","Net Debt (Interim)":"3,328.02","Net Debt (Annual)":"3,793.26","Dividend Yield (5Y)":"2.53","Dividend Yield":"1.70","Current Dividend Yield (TTM)":"1.70"},"Financial Strength":{"Free Cash Flow (Annual)":"-4,186.73","Current Ratio (Annual)":"1.86","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"23.13","Payout Ratio (Annual)":"49.54","Quick Ratio (Annual)":"1.56","Total Debt/Total Equity (Annual)":"50.41","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"2.15","Long Term Debt/Equity (Quarterly)":"24.44","Quick Ratio (Quarterly)":"1.83","Total Debt/Total Equity (Quarterly)":"47.51","Free Cash Flow (TTM)":"-3,855.38","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"41.98"},"Margins":{"Gross Margin (Annual)":"47.04","Gross Margin (TTM)":"47.39","Net Profit Margin % (Annual)":"28.56","Net Profit Margin (TTM)":"30.53","Operating Margin (Annual)":"33.68","Operating Margin (TTM)":"36.12","Pretax Margin (TTM)":"36.00","Pretax Margin (Annual)":"33.71","Operating Margin (5Y)":"32.98","Pretax Margin (5Y)":"33.19","Free Operating Cash Flow/Revenue (5Y)":"-24.83","Free Operating Cash Flow/Revenue (TTM)":"-45.87","Gross Margin (5Y)":"46.52","Net Profit Margin (5Y)":"27.70"},"Management Effectiveness":{"Return on Assets (Annual)":"8.63","Return on Equity (TTM)":"9.77","Return on Average Equity (Annual)":"13.14","Return on Average equity (TTM)":"14.87","Return on Investment (Annual)":"11.16","Return on Investment (TTM)":"12.45","Return on Average Assets (5Y)":"10.75","Return on Average Equity (5Y)":"14.97","Return on Investment (5Y)":"13.69","Asset Turnover (Annual)":"0.30","Asset Turnover (TTM)":"0.32","Inventory Turnover (Annual)":"2.32","Inventory Turnover (TTM)":"2.54","Net Income/Employee (Annual)":"231,400.70","Net Income/Employee (TTM)":"257,305.40","Receivables Turnover (Annual)":"4.66","Receivables Turnover (TTM)":"4.47","Revenue/Employee (Annual)":"810,225.70","Revenue/Employee (TTM)":"842,899.90"},"Growth":{"Revenue Growth (Quarterly YoY)":"42.68","Revenue Growth Rate (5Y)":"12.85","EPS Growth (Quarterly YoY)":"76.52","EPS Growth (TTM YoY)":"22.12","EPS Growth Rate (5Y)":"18.25","Dividend Growth Rate (3Y)":"12.31","Revenue Growth (TTM YoY)":"12.45","Revenue Growth (Per Share 5Y)":"9.53","Revenue Growth Rate (3Y)":"17.51","EPS Growth Rate (3Y)":"15.82","Book Value Growth Rate (Per Share 5Y)":"15.65","Tangible Book Value Total Equity CAGR (5Y)":"18.64","Capital Spending growth rate 5 year":"44.30","EBITDA CAGR (5Y)":"16.87","EBITDA Interim CAGR (5Y)":"25.98","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"48.27","Net Profit Margin Growth Rate (5Y)":"8.04"},"Income Statement":{"Revenue (Annual)":"7,620.98","Revenue (TTM)":"8,404.56","EBITD (Annual)":"3,063.30","EBITD (TTM)":"2,979.01","Earnings Before Taxes (Annual)":"2,568.69","Earnings Before Taxes (TTM)":"3,025.91","Net Income to Common (Annual)":"2,168.62","Net Income to Common (TTM)":"2,559.26","Earnings Before Taxes Normalized (Annual)":"2,537.45","Net Income Available to Common Normalized (Annual)":"2,142.14","Diluted Normalized EPS excl. Extra Items (TTM)":"1.18"}}}